Table 1.
The list of Genome-wide summary association studies (GWAS) included in the Mendelian randomization study.
| Exposures | GWAS ID | Population | Year | Consortium | Participants | No. SNP |
|---|---|---|---|---|---|---|
| Omega-3 FAs | met-d-Omega_3 | European | 2020 | UK biobank | 114,999 | 12,321,875 |
| Omega-6 FAs | met-d-Omega_6 | European | 2020 | UK biobank | 114,999 | 12,321,875 |
| Linoleic acid | met-d-LA | European | 2020 | UK biobank | 114,999 | 12,321,875 |
| DHA | met-d-DHA | European | 2020 | UK biobank | 114,999 | 12,321,875 |
| RO63 | met-d-Omega_6_by_ Omega_3 | European | 2020 | UK biobank | 114,999 | 12,321,875 |
| Outcome | GWAS ID | Population | Year | Consortium | Participants | No. SNP |
|---|---|---|---|---|---|---|
| Atypical facial pain | finn-b-G6_ATYFAC | European | 2021 | Finn Gen | 701 cases/195,047 controls | 16,380,408 |
| Pain in throat and chest | finn-b-R18_PAIN_ THROAT_CHEST | European | 2021 | Finn Gen | 24,609 cases/ 163,123 controls | 16,380,345 |
| Abdominal and pelvic pain | finn-b-R18_ABDOMI_ PELVIC_PAIN | European | 2021 | Finn Gen | 49,416cases/ 161,968 controls | 16,380,396 |
| Lower back pain or/and sciatica | finn-b-M13_LOWBACK PAINORANDSCIATICA | European | 2021 | Finn Gen | 19,509 cases/ 199,283 controls | 16,380,466 |
| Pain in joint | finn-b-JOINTPAIN | European | 2021 | Finn Gen | 13,419 cases/ 131,550 controls | 16,380,073 |
| Pain in limb | finn-b-M13_LIMBPAIN | European | 2021 | Finn Gen | 12,606 cases/ 167,641 controls | 16,380,354 |
| Low back pain | finn-b-M13_LOWBACK PAIN | European | 2021 | Finn Gen | 13,178 cases/ 164,682 controls | 16,380,287 |
| Gynecological related pain | finn-b-N14_FEMGEN PAIN | European | 2021 | Finn Gen | 3,316 cases/ 68,969 controls | 16,376,838 |
FAs, fatty acids; DHA, Docosahexaenoic acid; No. SNP, number of SNPs included in the analysis; RO63, ratio of omega-6 fatty acids to omega-3 fatty acids; Gynecological related pain, pain and other conditions associated with female genital organs and menstrual cycle.